Characterization of nonalcoholic fatty liver disease unrelated to the metabolic syndrome
Eur J Clin Invest 2012; 42 (4): 411–418 Background Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome (MS). However, not all patients with the MS will develop NAFLD and not all patients with NAFLD have the MS. We sought to investigate the differences bet...
Saved in:
Published in: | European journal of clinical investigation Vol. 42; no. 4; pp. 411 - 418 |
---|---|
Main Authors: | , , , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
Oxford, UK
Blackwell Publishing Ltd
01-04-2012
Wiley-Blackwell |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Abstract | Eur J Clin Invest 2012; 42 (4): 411–418
Background Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome (MS). However, not all patients with the MS will develop NAFLD and not all patients with NAFLD have the MS. We sought to investigate the differences between patients with biopsy‐proven NAFLD with and without the MS.
Methods A total of 357 consecutive patients with biopsy‐proven NAFLD were analysed. Of them, 216 patients had nonalcoholic steatohepatitis (NASH) and 96 a fibrosis score ≥ 2. The MS was defined as ≥ 3 of the ATP III criteria.
Results A total of 214 patients with NAFLD met the criteria for the MS, while the remaining 143 did not. In NAFLD patients with the MS, homeostasis model of insulin resistance (P = 0·03; OR, 1·06; 95% CI, 1·023–1·25 per unit increase) and diabetes (P = 0·01; OR, 1·2; 95% CI, 1·1–2·4) were independent predictors of NASH. In NAFLD patients without the MS, the only variable independently associated with NASH was haemoglobin (P = 0·007; OR, 1·9; 95% CI, 1·4–3·6 per 50 g/L increase). Alanine aminotransferase (P = 0·03; OR, 1·04; 95% CI, 1·006–1·11 per 10 U/L increase) was an independent predictor of fibrosis ≥ 2 in NAFLD patients with the MS, while haemoglobin (P = 0·02; OR, 1·4; 95% CI, 1·2–1·9 per 50 g/L increase) was the only variable significantly associated with fibrosis ≥ 2 in NAFLD patients without the MS.
Conclusions Increased haemoglobin in NAFLD subjects without MS should be considered in the selection of cases for histological assessment. |
---|---|
AbstractList | Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome (MS). However, not all patients with the MS will develop NAFLD and not all patients with NAFLD have the MS. We sought to investigate the differences between patients with biopsy-proven NAFLD with and without the MS.
A total of 357 consecutive patients with biopsy-proven NAFLD were analysed. Of them, 216 patients had nonalcoholic steatohepatitis (NASH) and 96 a fibrosis score ≥ 2. The MS was defined as ≥ 3 of the ATP III criteria.
A total of 214 patients with NAFLD met the criteria for the MS, while the remaining 143 did not. In NAFLD patients with the MS, homeostasis model of insulin resistance (P = 0·03; OR, 1·06; 95% CI, 1·023-1·25 per unit increase) and diabetes (P = 0·01; OR, 1·2; 95% CI, 1·1-2·4) were independent predictors of NASH. In NAFLD patients without the MS, the only variable independently associated with NASH was haemoglobin (P = 0·007; OR, 1·9; 95% CI, 1·4-3·6 per 50 g/L increase). Alanine aminotransferase (P = 0·03; OR, 1·04; 95% CI, 1·006-1·11 per 10 U/L increase) was an independent predictor of fibrosis ≥ 2 in NAFLD patients with the MS, while haemoglobin (P = 0·02; OR, 1·4; 95% CI, 1·2-1·9 per 50 g/L increase) was the only variable significantly associated with fibrosis ≥ 2 in NAFLD patients without the MS.
Increased haemoglobin in NAFLD subjects without MS should be considered in the selection of cases for histological assessment. BACKGROUNDNonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome (MS). However, not all patients with the MS will develop NAFLD and not all patients with NAFLD have the MS. We sought to investigate the differences between patients with biopsy-proven NAFLD with and without the MS.METHODSA total of 357 consecutive patients with biopsy-proven NAFLD were analysed. Of them, 216 patients had nonalcoholic steatohepatitis (NASH) and 96 a fibrosis score ≥ 2. The MS was defined as ≥ 3 of the ATP III criteria.RESULTSA total of 214 patients with NAFLD met the criteria for the MS, while the remaining 143 did not. In NAFLD patients with the MS, homeostasis model of insulin resistance (P = 0·03; OR, 1·06; 95% CI, 1·023-1·25 per unit increase) and diabetes (P = 0·01; OR, 1·2; 95% CI, 1·1-2·4) were independent predictors of NASH. In NAFLD patients without the MS, the only variable independently associated with NASH was haemoglobin (P = 0·007; OR, 1·9; 95% CI, 1·4-3·6 per 50 g/L increase). Alanine aminotransferase (P = 0·03; OR, 1·04; 95% CI, 1·006-1·11 per 10 U/L increase) was an independent predictor of fibrosis ≥ 2 in NAFLD patients with the MS, while haemoglobin (P = 0·02; OR, 1·4; 95% CI, 1·2-1·9 per 50 g/L increase) was the only variable significantly associated with fibrosis ≥ 2 in NAFLD patients without the MS.CONCLUSIONSIncreased haemoglobin in NAFLD subjects without MS should be considered in the selection of cases for histological assessment. Eur J Clin Invest 2012; 42 (4): 411–418 Background Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome (MS). However, not all patients with the MS will develop NAFLD and not all patients with NAFLD have the MS. We sought to investigate the differences between patients with biopsy‐proven NAFLD with and without the MS. Methods A total of 357 consecutive patients with biopsy‐proven NAFLD were analysed. Of them, 216 patients had nonalcoholic steatohepatitis (NASH) and 96 a fibrosis score ≥ 2. The MS was defined as ≥ 3 of the ATP III criteria. Results A total of 214 patients with NAFLD met the criteria for the MS, while the remaining 143 did not. In NAFLD patients with the MS, homeostasis model of insulin resistance (P = 0·03; OR, 1·06; 95% CI, 1·023–1·25 per unit increase) and diabetes (P = 0·01; OR, 1·2; 95% CI, 1·1–2·4) were independent predictors of NASH. In NAFLD patients without the MS, the only variable independently associated with NASH was haemoglobin (P = 0·007; OR, 1·9; 95% CI, 1·4–3·6 per 50 g/L increase). Alanine aminotransferase (P = 0·03; OR, 1·04; 95% CI, 1·006–1·11 per 10 U/L increase) was an independent predictor of fibrosis ≥ 2 in NAFLD patients with the MS, while haemoglobin (P = 0·02; OR, 1·4; 95% CI, 1·2–1·9 per 50 g/L increase) was the only variable significantly associated with fibrosis ≥ 2 in NAFLD patients without the MS. Conclusions Increased haemoglobin in NAFLD subjects without MS should be considered in the selection of cases for histological assessment. |
Author | Ayyildiz, Talat Dolar, Enver Senates, Ebubekir Tuncer, Ilyas Yilmaz, Yusuf Ovunc, Ayse Oya Kurdas Colak, Yasar Kalayci, Cem |
Author_xml | – sequence: 1 givenname: Yusuf surname: Yilmaz fullname: Yilmaz, Yusuf organization: Department of Gastroenterology, Marmara University, School of Medicine, Pendik, Istanbul, Turkey – sequence: 2 givenname: Ebubekir surname: Senates fullname: Senates, Ebubekir organization: Department of Gastroenterology, Haydarpasa Numune Education and Research Hospital, Istanbul, Turkey – sequence: 3 givenname: Talat surname: Ayyildiz fullname: Ayyildiz, Talat organization: Department of Gastroenterology, Uludag University Medical School, Bursa, Turkey – sequence: 4 givenname: Yasar surname: Colak fullname: Colak, Yasar organization: Department of Gastroenterology, Goztepe Education and Research Hospital, Istanbul, Turkey – sequence: 5 givenname: Ilyas surname: Tuncer fullname: Tuncer, Ilyas organization: Department of Gastroenterology, Goztepe Education and Research Hospital, Istanbul, Turkey – sequence: 6 givenname: Ayse Oya Kurdas surname: Ovunc fullname: Ovunc, Ayse Oya Kurdas organization: Department of Gastroenterology, Haydarpasa Numune Education and Research Hospital, Istanbul, Turkey – sequence: 7 givenname: Enver surname: Dolar fullname: Dolar, Enver organization: Department of Gastroenterology, Uludag University Medical School, Bursa, Turkey – sequence: 8 givenname: Cem surname: Kalayci fullname: Kalayci, Cem organization: Department of Gastroenterology, Marmara University, School of Medicine, Pendik, Istanbul, Turkey |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25589721$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/21913918$$D View this record in MEDLINE/PubMed |
BookMark | eNqNkU1v1DAQhi1URLeFv4B8QZwS_BEn9oED2palUvk4FIG4WBPH1npJ4mJ7YZdfT9Jdliu-2NI8r2f0zAU6G8NoEcKUlHQ6rzYl5bUoGK9ZyQilJWFCNeXuEVqcCmdoQQitCqYado4uUtoQQiTl7Ak6Z1RRrqhcoK_LNUQw2Ub_G7IPIw4OT92gN2Edem-wg5z3uPc_bcSdTxaSxdsx2h6y7XAOOK8tHmyG9gFP-7GLYbBP0WMHfbLPjvcl-vz2-m75rrj9uLpZvrktTMXrpqC1qWUjW6Zc1SnWMkels0JWdSOZMhQMM4zUIDgIB6C4IoI6Z0nXgms7zi_Ry8O_9zH82NqU9eCTsX0Pow3bpBWTishKiomUB9LEkFK0Tt9HP0Dca0r0rFVv9GxPz_b0rFU_aNW7Kfr82GTbDrY7Bf96nIAXRwCSgd5FGI1P_zgh5LQGOnGvD9wv39v9fw-gr5c382vKF4e8T9nuTnmI33Xd8EboLx9WelVfvf8kv93pK_4H7culRg |
CitedBy_id | crossref_primary_10_3390_ijms17030281 crossref_primary_10_1097_MEG_0000000000000434 crossref_primary_10_12677_ACM_2022_121050 crossref_primary_10_3390_ijerph17061818 crossref_primary_10_3748_wjg_v20_i39_14219 crossref_primary_10_1089_met_2012_0147 crossref_primary_10_1159_000438473 crossref_primary_10_3109_00365521_2014_983160 crossref_primary_10_1111_apt_12255 crossref_primary_10_1097_MEG_0000000000000342 crossref_primary_10_1155_2013_124958 crossref_primary_10_14218_JCTH_2016_00068 crossref_primary_10_29058_mjwbs_811398 crossref_primary_10_5009_gnl_2014_8_3_313 crossref_primary_10_1097_MEG_0000000000000409 crossref_primary_10_1016_j_dld_2016_10_004 crossref_primary_10_3109_00365521_2014_958099 crossref_primary_10_3390_ijms19071977 crossref_primary_10_4254_wjh_v4_i12_332 crossref_primary_10_1016_j_cca_2012_04_019 crossref_primary_10_1371_journal_pone_0171502 crossref_primary_10_1186_s12872_021_02060_z crossref_primary_10_1038_s41598_018_31845_0 crossref_primary_10_1097_MEG_0000000000000254 crossref_primary_10_1016_j_diabres_2018_08_011 crossref_primary_10_1097_MEG_0000000000000255 crossref_primary_10_1017_S1368980015002293 |
Cites_doi | 10.2174/138161210791208875 10.1055/s-2001-12927 10.1111/j.1365-2362.2009.02234.x 10.1038/ncpendmet0505 10.1161/01.CIR.0000111245.75752.C6 10.1161/CIRCULATIONAHA.105.169404 10.1016/j.mcna.2007.06.001 10.1002/pmic.200300495 10.1016/S0140-6736(05)67402-8 10.1111/j.1751-2980.2008.00331.x 10.1002/hep.20466 10.1074/jbc.M702163200 10.1161/ATVBAHA.107.147538 10.1136/gut.2009.186668 10.1042/CS20070402 10.1053/jhep.2003.50161 10.1017/S0029665110000030 10.1089/152308601300185250 10.1136/gut.2007.140087 10.1002/hep.22622 10.1016/j.dld.2010.01.016 10.1042/BJ20071570 10.1111/j.1572-0241.1999.01377.x 10.1053/jhep.2003.50325 10.1002/hep.20701 10.1053/jhep.2003.50193 10.1007/s11894-008-0012-0 10.1111/j.1365-2613.2008.00590.x 10.3949/ccjm.75.10.721 10.1016/j.annepidem.2007.05.013 10.1161/01.CIR.0000133317.49796.0E 10.3109/03630260903346676 |
ContentType | Journal Article |
Copyright | 2011 The Authors. European Journal of Clinical Investigation © 2011 Stichting European Society for Clinical Investigation Journal Foundation 2015 INIST-CNRS 2011 The Authors. European Journal of Clinical Investigation © 2011 Stichting European Society for Clinical Investigation Journal Foundation. |
Copyright_xml | – notice: 2011 The Authors. European Journal of Clinical Investigation © 2011 Stichting European Society for Clinical Investigation Journal Foundation – notice: 2015 INIST-CNRS – notice: 2011 The Authors. European Journal of Clinical Investigation © 2011 Stichting European Society for Clinical Investigation Journal Foundation. |
DBID | BSCLL IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
DOI | 10.1111/j.1365-2362.2011.02597.x |
DatabaseName | Istex Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1365-2362 |
EndPage | 418 |
ExternalDocumentID | 10_1111_j_1365_2362_2011_02597_x 21913918 25589721 ECI2597 ark_67375_WNG_G6DMP8ZT_D |
Genre | article Journal Article |
GroupedDBID | --- -~X .3N .55 .GA .GJ .Y3 05W 0R~ 10A 1OB 1OC 29G 31~ 33P 36B 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5RE 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AANLZ AAONW AASGY AAXRX AAZKR ABCQN ABCUV ABDBF ABEML ABLJU ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACGOF ACIWK ACMXC ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFNX AFFPM AFGKR AFPWT AFRAH AFZJQ AHBTC AHEFC AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BSCLL BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 DUUFO EAD EAP EAS EBB EBC EBD EBS EBX EJD EMB EMK EMOBN EPT ESX EX3 F00 F01 F04 F5P FEDTE FUBAC FZ0 G-S G.N GODZA H.X HF~ HGLYW HVGLF HZI HZ~ IHE IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK0 MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PALCI Q.N Q11 QB0 Q~Q R.K RIWAO RJQFR ROL RX1 SAMSI SUPJJ SV3 TEORI TUS UB1 W8V W99 WBKPD WH7 WHWMO WIH WIJ WIK WOHZO WOW WQJ WRC WUP WVDHM WXI WXSBR X7M XG1 YFH ZGI ZXP ZZTAW ~IA ~WT 08R AAPBV AAUGY AAVGM ABHUG ABPTK ACXME ADAWD ADDAD AFVGU AGJLS AKALU IQODW ZA5 CGR CUY CVF ECM EIF NPM AAMNL AAYXX CITATION 7X8 |
ID | FETCH-LOGICAL-c4367-16c6878b29f4d92b2f18fe58467829c1ac2c206a53a5faa939051ffe0dbafbd33 |
IEDL.DBID | 33P |
ISSN | 0014-2972 |
IngestDate | Sat Aug 17 02:50:35 EDT 2024 Thu Nov 21 23:09:27 EST 2024 Sat Sep 28 08:01:07 EDT 2024 Sun Oct 22 16:05:34 EDT 2023 Sat Aug 24 01:15:17 EDT 2024 Wed Oct 30 09:53:40 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 4 |
Keywords | Endocrinopathy Pancreatic hormone Digestive system Unrelated donor Liver Metabolic diseases Cardiovascular disease Hepatic disease Metabolic syndrome Insulin Steatosis Characterization Medicine nonalcoholic steatohepatitis Target tissue resistance haemoglobin Non alcoholic steatohepatitis Fibrosis Hemoglobin Digestive diseases Insulin resistance |
Language | English |
License | CC BY 4.0 2011 The Authors. European Journal of Clinical Investigation © 2011 Stichting European Society for Clinical Investigation Journal Foundation. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c4367-16c6878b29f4d92b2f18fe58467829c1ac2c206a53a5faa939051ffe0dbafbd33 |
Notes | ArticleID:ECI2597 istex:47CADE98ECBD9DCCCF4121E650EA0554510AC07B ark:/67375/WNG-G6DMP8ZT-D ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PMID | 21913918 |
PQID | 928908485 |
PQPubID | 23479 |
PageCount | 8 |
ParticipantIDs | proquest_miscellaneous_928908485 crossref_primary_10_1111_j_1365_2362_2011_02597_x pubmed_primary_21913918 pascalfrancis_primary_25589721 wiley_primary_10_1111_j_1365_2362_2011_02597_x_ECI2597 istex_primary_ark_67375_WNG_G6DMP8ZT_D |
PublicationCentury | 2000 |
PublicationDate | April 2012 |
PublicationDateYYYYMMDD | 2012-04-01 |
PublicationDate_xml | – month: 04 year: 2012 text: April 2012 |
PublicationDecade | 2010 |
PublicationPlace | Oxford, UK |
PublicationPlace_xml | – name: Oxford, UK – name: Oxford – name: England |
PublicationTitle | European journal of clinical investigation |
PublicationTitleAlternate | Eur J Clin Invest |
PublicationYear | 2012 |
Publisher | Blackwell Publishing Ltd Wiley-Blackwell |
Publisher_xml | – name: Blackwell Publishing Ltd – name: Wiley-Blackwell |
References | Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003;37:917-23. Simera I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting guidelines for health research. Eur J Clin Invest 2010;40:35-53. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39. Bugianesi E, Moscatiello S, Ciaravella MF, Marchesini G. Insulin resistance in nonalcoholic fatty liver disease. Curr Pharm Des 2010;16:1941-51. Kotronen A, Yki-Järvinen H. Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008;28:27-38. Emanuele E. Is biopsy always necessary? Toward a clinico-laboratory approach for diagnosing nonalcoholic steatohepatitis in obesity. Hepatology 2008;48:2086-7. Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis 2001;21:27-41. Vanni E, Bugianesi E, Kotronen A, De Minicis S, Yki-Järvinen H, Svegliati-Baroni G. From the metabolic syndrome to NAFLD or vice versa? Dig Liver Dis 2010;42: 32030. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004;40:1387-95. Xu L, Xu CF, Yu CH, Miao M, Li YM. Haemoglobin and non-alcoholic fatty liver disease: further evidence from a population-based study. Gut 2009;58:1706-7. Zhang R, Barker L, Pinchev D, Marshall J, Rasamoelisolo M, Smith C et al. Mining biomarkers in human sera using proteomic tools. Proteomics 2004;4:244-56. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C; American Heart Association; National Heart, Lung, and Blood Institute. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004;109:433-8. Alayash AI, Patel RP, Cashon RE. Redox reactions of hemoglobin and myoglobin: biological and toxicological implications. Antioxid Redox Signal 2001;3:313-27. Perlemuter G, Bigorgne A, Cassard-Doulcier AM, Naveau S. Nonalcoholic fatty liver disease: from pathogenesis to patient care. Nat Clin Pract Endocrinol Metab 2007;3:458-69. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003;37:1202-19. Wallace K, Burt AD, Wright MC. Liver fibrosis. Biochem J 2008;411:1-18. Adams LA, Lindor KD. Nonalcoholic fatty liver disease. Ann Epidemiol 2007;17:863-9. Duvnjak L, Duvnjak M. The metabolic syndrome - an ongoing story. J Physiol Pharmacol 2009;60(Suppl. 7):19-24. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-21. Watanabe J, Chou KJ, Liao JC, Miao Y, Meng HH, Ge H et al. Differential association of hemoglobin with proinflammatory high density lipoproteins in atherogenic/hyperlipidemic mice. A novel biomarker of atherosclerosis. J Biol Chem 2007;282:23698-707. Leung TM, Tipoe GL, Liong EC, Lau TY, Fung ML, Nanji AA. Endothelial nitric oxide synthase is a critical factor in experimental liver fibrosis. Int J Exp Pathol 2008;89:241-50. Taher AT, Musallam KM, Inati A. Iron overload: consequences, assessment, and monitoring. Hemoglobin 2009;33:S46-57. Zeng MD, Fan JG, Lu LG, Li YM, Chen CW, Wang BY et al. Guidelines for the diagnosis and treatment of nonalcoholic fatty liver diseases. J Dig Dis 2008;9:108-12. Khashab MA, Liangpunsakul S, Chalasani N. Nonalcoholic fatty liver disease as a component of the metabolic syndrome. Curr Gastroenterol Rep 2008;10:73-80. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 2005;112:2735-52. Preiss D, Sattar N. Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations. Clin Sci (Lond) 2008;115:141-50. Trak-Smayra V, Dargere D, Noun R, Albuquerque M, Yaghi C, Gannagé-Yared MH et al. Serum proteomic profiling of obese patients: correlation with liver pathology and evolution after bariatric surgery. Gut 2009;58:825-32. Abdelmalek MF, Diehl AM. Nonalcoholic fatty liver disease as a complication of insulin resistance. Med Clin North Am 2007;91:1125-49. Kim CH, Younossi ZM. Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome. Cleve Clin J Med 2008;75:721-8. Alberti KG, Zimmet P, Shaw J; for the IDF Epidemiology Task Force Consensus Group. The metabolic syndrome: a new worldwide definition. Lancet 2005;366:1059-62. Moore JB. Non-alcoholic fatty liver disease: the hepatic consequence of obesity and the metabolic syndrome. Proc Nutr Soc 2010;69:211-20. Pearson TC. Hemorheology in the erythrocytoses. Mt Sinai J Med 2001;68:182-91. Green RM. NASH - hepatic metabolism and not simply the metabolic syndrome. Hepatology 2003;38:14-7. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999;94:2467-74. 2007; 17 2010; 16 2004; 40 2007; 282 2005; 112 2009; 60 2008; 9 2004; 4 2005; 41 2003; 37 2007; 91 2003; 38 2008; 10 2008; 75 2004; 109 2001; 68 2010; 40 2001; 21 2009; 33 2004; 110 2009; 58 2010; 42 2010; 69 2005; 366 2008; 28 2008; 48 2008; 89 2001; 3 2008; 115 2008; 411 2007; 3 1999; 94 e_1_2_8_27_2 e_1_2_8_28_2 e_1_2_8_29_2 e_1_2_8_23_2 e_1_2_8_24_2 e_1_2_8_25_2 e_1_2_8_26_2 e_1_2_8_9_2 e_1_2_8_2_2 Pearson TC (e_1_2_8_30_2) 2001; 68 e_1_2_8_4_2 e_1_2_8_3_2 e_1_2_8_6_2 e_1_2_8_5_2 e_1_2_8_8_2 e_1_2_8_7_2 e_1_2_8_20_2 e_1_2_8_21_2 e_1_2_8_22_2 e_1_2_8_16_2 Duvnjak L (e_1_2_8_11_2) 2009; 60 e_1_2_8_17_2 e_1_2_8_18_2 e_1_2_8_19_2 e_1_2_8_12_2 e_1_2_8_35_2 e_1_2_8_13_2 e_1_2_8_34_2 e_1_2_8_14_2 e_1_2_8_15_2 e_1_2_8_31_2 e_1_2_8_10_2 e_1_2_8_33_2 e_1_2_8_32_2 |
References_xml | – volume: 115 start-page: 141 year: 2008 end-page: 50 article-title: Non‐alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations publication-title: Clin Sci (Lond) – volume: 33 start-page: S46 year: 2009 end-page: 57 article-title: Iron overload: consequences, assessment, and monitoring publication-title: Hemoglobin – volume: 16 start-page: 1941 year: 2010 end-page: 51 article-title: Insulin resistance in nonalcoholic fatty liver disease publication-title: Curr Pharm Des – volume: 37 start-page: 917 year: 2003 end-page: 23 article-title: Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome publication-title: Hepatology – volume: 3 start-page: 458 year: 2007 end-page: 69 article-title: Nonalcoholic fatty liver disease: from pathogenesis to patient care publication-title: Nat Clin Pract Endocrinol Metab – volume: 48 start-page: 2086 year: 2008 end-page: 7 article-title: Is biopsy always necessary? Toward a clinico‐laboratory approach for diagnosing nonalcoholic steatohepatitis in obesity publication-title: Hepatology – volume: 112 start-page: 2735 year: 2005 end-page: 52 article-title: Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement publication-title: Circulation – volume: 89 start-page: 241 year: 2008 end-page: 50 article-title: Endothelial nitric oxide synthase is a critical factor in experimental liver fibrosis publication-title: Int J Exp Pathol – volume: 37 start-page: 1202 year: 2003 end-page: 19 article-title: Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference publication-title: Hepatology – volume: 40 start-page: 1387 year: 2004 end-page: 95 article-title: Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity publication-title: Hepatology – volume: 40 start-page: 35 year: 2010 end-page: 53 article-title: A catalogue of reporting guidelines for health research publication-title: Eur J Clin Invest – volume: 282 start-page: 23698 year: 2007 end-page: 707 article-title: Differential association of hemoglobin with proinflammatory high density lipoproteins in atherogenic/hyperlipidemic mice. A novel biomarker of atherosclerosis publication-title: J Biol Chem – volume: 10 start-page: 73 year: 2008 end-page: 80 article-title: Nonalcoholic fatty liver disease as a component of the metabolic syndrome publication-title: Curr Gastroenterol Rep – volume: 9 start-page: 108 year: 2008 end-page: 12 article-title: Guidelines for the diagnosis and treatment of nonalcoholic fatty liver diseases publication-title: J Dig Dis – volume: 41 start-page: 1313 year: 2005 end-page: 21 article-title: Design and validation of a histological scoring system for nonalcoholic fatty liver disease publication-title: Hepatology – volume: 94 start-page: 2467 year: 1999 end-page: 74 article-title: Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions publication-title: Am J Gastroenterol – volume: 411 start-page: 1 year: 2008 end-page: 18 article-title: Liver fibrosis publication-title: Biochem J – volume: 42 year: 2010 article-title: From the metabolic syndrome to NAFLD or vice versa? publication-title: Dig Liver Dis – volume: 109 start-page: 433 year: 2004 end-page: 8 article-title: Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition publication-title: Circulation – volume: 38 start-page: 14 year: 2003 end-page: 7 article-title: NASH – hepatic metabolism and not simply the metabolic syndrome publication-title: Hepatology – volume: 68 start-page: 182 year: 2001 end-page: 91 article-title: Hemorheology in the erythrocytoses publication-title: Mt Sinai J Med – volume: 366 start-page: 1059 year: 2005 end-page: 62 article-title: The metabolic syndrome: a new worldwide definition publication-title: Lancet – volume: 58 start-page: 825 year: 2009 end-page: 32 article-title: Serum proteomic profiling of obese patients: correlation with liver pathology and evolution after bariatric surgery publication-title: Gut – volume: 110 start-page: 227 year: 2004 end-page: 39 article-title: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines publication-title: Circulation – volume: 91 start-page: 1125 year: 2007 end-page: 49 article-title: Nonalcoholic fatty liver disease as a complication of insulin resistance publication-title: Med Clin North Am – volume: 58 start-page: 1706 year: 2009 end-page: 7 article-title: Haemoglobin and non‐alcoholic fatty liver disease: further evidence from a population‐based study publication-title: Gut – volume: 75 start-page: 721 year: 2008 end-page: 8 article-title: Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome publication-title: Cleve Clin J Med – volume: 21 start-page: 27 year: 2001 end-page: 41 article-title: Etiopathogenesis of nonalcoholic steatohepatitis publication-title: Semin Liver Dis – volume: 28 start-page: 27 year: 2008 end-page: 38 article-title: Fatty liver: a novel component of the metabolic syndrome publication-title: Arterioscler Thromb Vasc Biol – volume: 60 start-page: 19 issue: Suppl. 7 year: 2009 end-page: 24 article-title: The metabolic syndrome – an ongoing story publication-title: J Physiol Pharmacol – volume: 3 start-page: 313 year: 2001 end-page: 27 article-title: Redox reactions of hemoglobin and myoglobin: biological and toxicological implications publication-title: Antioxid Redox Signal – volume: 69 start-page: 211 year: 2010 end-page: 20 article-title: Non‐alcoholic fatty liver disease: the hepatic consequence of obesity and the metabolic syndrome publication-title: Proc Nutr Soc – volume: 17 start-page: 863 year: 2007 end-page: 9 article-title: Nonalcoholic fatty liver disease publication-title: Ann Epidemiol – volume: 4 start-page: 244 year: 2004 end-page: 56 article-title: Mining biomarkers in human sera using proteomic tools publication-title: Proteomics – ident: e_1_2_8_7_2 doi: 10.2174/138161210791208875 – ident: e_1_2_8_15_2 doi: 10.1055/s-2001-12927 – ident: e_1_2_8_18_2 doi: 10.1111/j.1365-2362.2009.02234.x – ident: e_1_2_8_9_2 doi: 10.1038/ncpendmet0505 – ident: e_1_2_8_12_2 doi: 10.1161/01.CIR.0000111245.75752.C6 – ident: e_1_2_8_34_2 doi: 10.1161/CIRCULATIONAHA.105.169404 – ident: e_1_2_8_8_2 doi: 10.1016/j.mcna.2007.06.001 – ident: e_1_2_8_28_2 doi: 10.1002/pmic.200300495 – volume: 60 start-page: 19 issue: 7 year: 2009 ident: e_1_2_8_11_2 article-title: The metabolic syndrome – an ongoing story publication-title: J Physiol Pharmacol contributor: fullname: Duvnjak L – ident: e_1_2_8_35_2 doi: 10.1016/S0140-6736(05)67402-8 – ident: e_1_2_8_19_2 doi: 10.1111/j.1751-2980.2008.00331.x – ident: e_1_2_8_2_2 doi: 10.1002/hep.20466 – ident: e_1_2_8_29_2 doi: 10.1074/jbc.M702163200 – ident: e_1_2_8_6_2 doi: 10.1161/ATVBAHA.107.147538 – ident: e_1_2_8_26_2 doi: 10.1136/gut.2009.186668 – volume: 68 start-page: 182 year: 2001 ident: e_1_2_8_30_2 article-title: Hemorheology in the erythrocytoses publication-title: Mt Sinai J Med contributor: fullname: Pearson TC – ident: e_1_2_8_4_2 doi: 10.1042/CS20070402 – ident: e_1_2_8_22_2 doi: 10.1053/jhep.2003.50161 – ident: e_1_2_8_5_2 doi: 10.1017/S0029665110000030 – ident: e_1_2_8_27_2 doi: 10.1089/152308601300185250 – ident: e_1_2_8_25_2 doi: 10.1136/gut.2007.140087 – ident: e_1_2_8_33_2 doi: 10.1002/hep.22622 – ident: e_1_2_8_16_2 doi: 10.1016/j.dld.2010.01.016 – ident: e_1_2_8_24_2 doi: 10.1042/BJ20071570 – ident: e_1_2_8_20_2 doi: 10.1111/j.1572-0241.1999.01377.x – ident: e_1_2_8_17_2 doi: 10.1053/jhep.2003.50325 – ident: e_1_2_8_21_2 doi: 10.1002/hep.20701 – ident: e_1_2_8_3_2 doi: 10.1053/jhep.2003.50193 – ident: e_1_2_8_14_2 doi: 10.1007/s11894-008-0012-0 – ident: e_1_2_8_31_2 doi: 10.1111/j.1365-2613.2008.00590.x – ident: e_1_2_8_13_2 doi: 10.3949/ccjm.75.10.721 – ident: e_1_2_8_10_2 doi: 10.1016/j.annepidem.2007.05.013 – ident: e_1_2_8_23_2 doi: 10.1161/01.CIR.0000133317.49796.0E – ident: e_1_2_8_32_2 doi: 10.3109/03630260903346676 |
SSID | ssj0008132 |
Score | 2.2504466 |
Snippet | Eur J Clin Invest 2012; 42 (4): 411–418
Background Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome (MS).... Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome (MS). However, not all patients with the MS will develop NAFLD... BACKGROUNDNonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome (MS). However, not all patients with the MS will... |
SourceID | proquest crossref pubmed pascalfrancis wiley istex |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 411 |
SubjectTerms | Adult Age Factors Biological and medical sciences Biomarkers - metabolism Biopsy Cross-Sectional Studies Fatty Liver - blood Fatty Liver - diagnosis Fatty Liver - physiopathology Female Fibrosis Gastroenterology. Liver. Pancreas. Abdomen General aspects haemoglobin Hemoglobins - metabolism Humans insulin resistance Liver. Biliary tract. Portal circulation. Exocrine pancreas Logistic Models Male Medical sciences Metabolic diseases Metabolic Syndrome - blood Metabolic Syndrome - diagnosis Metabolic Syndrome - physiopathology Middle Aged Miscellaneous Non-alcoholic Fatty Liver Disease nonalcoholic steatohepatitis Other diseases. Semiology Other metabolic disorders ROC Curve Severity of Illness Index Sex Factors Turkey |
Title | Characterization of nonalcoholic fatty liver disease unrelated to the metabolic syndrome |
URI | https://api.istex.fr/ark:/67375/WNG-G6DMP8ZT-D/fulltext.pdf https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1365-2362.2011.02597.x https://www.ncbi.nlm.nih.gov/pubmed/21913918 https://search.proquest.com/docview/928908485 |
Volume | 42 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEB6aFEIuTZtH66YJOpTeXFYP2_Kx7G4ehYRAExp6EbIeUJrsll0vpP--GsnrZEsOoeRmhMfYM5rRJ8_MJ4CP8ZSjgENz1miXC-tc3hhW5VZS4worRKJrOvlWnV_L0Rhpcr4ue2ESP0T_ww09I8ZrdHDdzFedPFZohQjcMXEGJF99RjwZNg2xm4Nf9EFZUp6Iw6nIWV39U9Tz6INWVqqXqPQ7rJzU86A8n069eAyWrqLcuEwdbT3nB76GVx1YJV_S7HoDL9xkGzbOunT8DlwPe7rn1M1Jpp5MENvHc3d_GuJ12_4hN1j8QbpcEFlMYgONs6SdkoA_ya1rw1TE25f8CbtwdTS-HJ7k3VENuRE8hFpamlJWsmG1F7ZmDfNUehfBjWS1odowwwalLrguvNY1R1ow793ANto3lvM9WA-v594B4Za7qqLaO8dFKeomIKCyHEhnTRHGbQZ0aRb1OzFyqAc7maAyhSpTqDIVVabuMvgU7dcL6NkvrGirCvX9_Fgdl6OzC_njUo0yOFwxcC8Qdl4SiY4yIEuLq-CImF3REzddzFWNKVspZJHB2zQT7oUpkq9SmUEZDf7k91bj4Slevf9fwX3YDMMslRp9gPV2tnAHsDa3i8PoH38BfCgLqg |
link.rule.ids | 315,782,786,1408,27933,27934,46064,46488 |
linkProvider | Wiley-Blackwell |
linkToHtml | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LTxsxEB5RkNpeWvqg3baAD1VvW8X2PrxHlASCIBFSUxX1Ynn9kBBtUpGNRP89HnuzNBUHhLitVp6Vd8Yz_myPvwH4HKoceRyaslrZNDPWprVmZWoE1TY3WRbpmkbfysm5GAyRJudkdRcm8kN0G27oGSFeo4PjhvS6l4cULR-CWypOD-XLrx5QbmWFH5d4n4OfdWFZUB6pw2mWsqr8L63nzi-tzVVbqPZrzJ1UC68-F-te3AVM13FumKgOXz7qL27DixavkoM4wF7Bhp29hqfj9kT-DZz3O8bneKGTzB2ZIbwPpXcvNHGqaf6SX5j_QdrjILKchTs01pBmTjwEJb9t40cjNl9RKLyF74fDaX-UttUaUp1xH21poQtRippVLjMVq5mjwtmAbwSrNFWaadYrVM5V7pSqODKDOWd7plauNpzvwKbvnn0PhBtuy5IqZy33pqxqD4KKoies0bl_bxKgK7vIP5GUQ_6zmPEqk6gyiSqTQWXyOoEvwYCdgLq6xKS2Mpc_JkfyqBiMz8TPqRwksLdm4U7AL74Ech0lQFYml94X8YBFzex8uZAVntqKTOQJvItD4VaYIv8qFQkUweL37rcc9o_x6cNDBffh2Wg6PpWnx5OTj_DcN2Ex8-gTbDZXS7sLTxZmuRec5QZzpg_S |
linkToPdf | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwEB5BK1VcypsGaPEBcQtaP5I4R7SPtkBXK1FExcVy_JAqYLfqZqXy7_HY2dCteqgQtyjKRM6MZ_w5M_4G4G3schRwaM4a7XJhncsbw6rcSmpcYYVIdE1HX6rpmRyNkSbn4_osTOKH6H-4oWfEeI0OfmH9ppPHCq0QgTsmzoDkq_cBT26LgMqRR5_zWR-VJeWJOZyKnNXVjaqeW9-0sVRto9avsHRSL4P2fGp7cRsu3YS5cZ2aPPyfX_gIdju0Sj6k6fUY7rn5E9g56fLxT-Fs2PM9p-OcZOHJHMF9bLx7bojXbfub_MTqD9Ilg8hqHk_QOEvaBQkAlPxybZiL-PiaQOEZfJ2MT4dHederITeCh1hLS1PKSjas9sLWrGGeSu8iupGsNlQbZtig1AXXhde65sgL5r0b2Eb7xnL-HLbC8NweEG65qyqqvXNclKJuAgQqy4F01hThvs2Ars2iLhIlh7q2lQkqU6gyhSpTUWXqKoN30X69gL78gSVtVaG-TQ_VYTk6mcnvp2qUwcGGgXuBsPWSyHSUAVlbXAVPxPSKnrvFaqlqzNlKIYsMXqSZ8FeYIvsqlRmU0eB3HrcaD4_x6uW_Cr6Bndlooj4fTz-9ggfhCZbKjl7DVnu5cvtwf2lXB9FV_gAFGw54 |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Characterization+of+nonalcoholic+fatty+liver+disease+unrelated+to+the+metabolic+syndrome&rft.jtitle=European+journal+of+clinical+investigation&rft.au=Yilmaz%2C+Yusuf&rft.au=Senates%2C+Ebubekir&rft.au=Ayyildiz%2C+Talat&rft.au=Colak%2C+Yasar&rft.date=2012-04-01&rft.pub=Blackwell+Publishing+Ltd&rft.issn=0014-2972&rft.eissn=1365-2362&rft.volume=42&rft.issue=4&rft.spage=411&rft.epage=418&rft_id=info:doi/10.1111%2Fj.1365-2362.2011.02597.x&rft.externalDBID=10.1111%252Fj.1365-2362.2011.02597.x&rft.externalDocID=ECI2597 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0014-2972&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0014-2972&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0014-2972&client=summon |